312 related articles for article (PubMed ID: 17065336)
1. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Szabó C; Biser A; Benko R; Böttinger E; Suszták K
Diabetes; 2006 Nov; 55(11):3004-12. PubMed ID: 17065336
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats.
Wan ZH; Li WZ; Li YZ; Chen L; Li GH; Hu WF; Peng S; Yu JJ; Guo F
J Sex Med; 2011 Apr; 8(4):1002-14. PubMed ID: 20807334
[TBL] [Abstract][Full Text] [Related]
3. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
4. Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Peixoto EB; Papadimitriou A; Lopes de Faria JM; Lopes de Faria JB
Nephron Exp Nephrol; 2012; 120(2):e81-90. PubMed ID: 22555049
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Zakaria EM; El-Maraghy NN; Ahmed AF; Ali AA; El-Bassossy HM
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jun; 390(6):621-631. PubMed ID: 28224182
[TBL] [Abstract][Full Text] [Related]
6. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy.
Drel VR; Xu W; Zhang J; Pavlov IA; Shevalye H; Slusher B; Obrosova IG
Endocrinology; 2009 Dec; 150(12):5273-83. PubMed ID: 19854869
[TBL] [Abstract][Full Text] [Related]
7. PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes.
Xu B; Chiu J; Feng B; Chen S; Chakrabarti S
Diabetes Metab Res Rev; 2008; 24(5):404-12. PubMed ID: 18351623
[TBL] [Abstract][Full Text] [Related]
8. Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina.
Goebel DJ; Winkler BS
J Neurochem; 2006 Sep; 98(6):1732-45. PubMed ID: 16903875
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Choi SK; Galán M; Kassan M; Partyka M; Trebak M; Matrougui K
Hypertension; 2012 May; 59(5):1060-8. PubMed ID: 22454481
[TBL] [Abstract][Full Text] [Related]
10. A dual role for poly(ADP-ribose) polymerase-1 during caspase-dependent apoptosis.
Zhang F; Lau SS; Monks TJ
Toxicol Sci; 2012 Jul; 128(1):103-14. PubMed ID: 22523229
[TBL] [Abstract][Full Text] [Related]
11. The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Lakatos P; Hegedűs C; Salazar Ayestarán N; Juarranz Á; Kövér KE; Szabó É; Virág L
Mutat Res; 2016 Aug; 790():31-40. PubMed ID: 27427773
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Xiao CY; Chen M; Zsengellér Z; Szabó C
J Pharmacol Exp Ther; 2004 Aug; 310(2):498-504. PubMed ID: 15054118
[TBL] [Abstract][Full Text] [Related]
13. Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP.
Chandak PG; Gaikwad AB; Tikoo K
Phytother Res; 2009 Jan; 23(1):72-7. PubMed ID: 18693296
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Xiao CY; Chen M; Zsengellér Z; Li H; Kiss L; Kollai M; Szabó C
J Pharmacol Exp Ther; 2005 Mar; 312(3):891-8. PubMed ID: 15523000
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat.
Besson VC; Zsengellér Z; Plotkine M; Szabó C; Marchand-Verrecchia C
Brain Res; 2005 Apr; 1041(2):149-56. PubMed ID: 15829224
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Radovits T; Lin LN; Zotkina J; Gero D; Szabó C; Karck M; Szabó G
Eur J Pharmacol; 2007 Jun; 564(1-3):158-66. PubMed ID: 17397824
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Shevalye H; Stavniichuk R; Xu W; Zhang J; Lupachyk S; Maksimchyk Y; Drel VR; Floyd EZ; Slusher B; Obrosova IG
Biochem Pharmacol; 2010 Apr; 79(7):1007-14. PubMed ID: 19945439
[TBL] [Abstract][Full Text] [Related]
18. Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance.
Gerace E; Scartabelli T; Formentini L; Landucci E; Moroni F; Chiarugi A; Pellegrini-Giampietro DE
Eur J Neurosci; 2012 Jul; 36(1):1993-2005. PubMed ID: 22639866
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Qin WD; Liu GL; Wang J; Wang H; Zhang JN; Zhang F; Ma Y; Ji XY; Li C; Zhang MX
Oncotarget; 2016 Jun; 7(24):35618-35631. PubMed ID: 27027354
[TBL] [Abstract][Full Text] [Related]
20. Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction.
Radovits T; Seres L; Gero D; Berger I; Szabó C; Karck M; Szabó G
Exp Gerontol; 2007 Jul; 42(7):676-85. PubMed ID: 17383839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
